TALTZ (ixekizumab), an IL-17A inhibitor by Eli Lilly, has shown strong market growth driven by increasing adoption in psoriasis, psoriatic arthritis, ...
Symbravo Outperforms Oral CGRP Inhibitors in Phase III Trial, With Faster, Sustained Migraine Relief
Data from the Phase III EMERGE trial show treatment with Symbravo provided more rapid and sustained migraine relief with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback